Contrasting LENZ Therapeutics (LENZ) & Its Rivals

LENZ Therapeutics (NASDAQ:LENZ) is one of 291 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare LENZ Therapeutics to related businesses based on the strength of its valuation, analyst recommendations, earnings, risk, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for LENZ Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1427	4560	11940	206	2.60

LENZ Therapeutics currently has a consensus target price of $31.33, suggesting a potential upside of 97.19%. As a group, “Biological products, except diagnostic” companies have a potential upside of 124.75%. Given LENZ Therapeutics’ rivals higher possible upside, analysts clearly believe LENZ Therapeutics has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares LENZ Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.02
LENZ Therapeutics Competitors	$543.23 million	-$37.31 million	5.89

LENZ Therapeutics’ rivals have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares LENZ Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,499.00%	-224.48%	-45.27%

Volatility and Risk

LENZ Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ rivals have a beta of 1.00, suggesting that their average share price is 0% less volatile than the S&P 500.

Summary

LENZ Therapeutics beats its rivals on 7 of the 13 factors compared.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.